Literature DB >> 21880641

Graft-versus-host disease therapy: something else beyond glucocorticoids?

Carmen Martínez, Alvaro Urbano-Ispízua.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21880641      PMCID： PMC3166093          DOI： 10.3324/haematol.2011.050534

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  23 in total

1.  The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.

Authors:  Suzanne van Dorp; Henrike Resemann; Liane te Boome; Floor Pietersma; Debbie van Baarle; Frits Gmelig-Meyling; Roel de Weger; Eefke Petersen; Monique Minnema; Henk Lokhorst; Saskia Ebeling; Scott J P Beijn; Edward F Knol; Marijke van Dijk; Ellen Meijer; Jürgen Kuball
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

Review 2.  The kaleidoscope of glucorticoid effects on immune system.

Authors:  Margherita Zen; Mariagrazia Canova; Carla Campana; Silvano Bettio; Linda Nalotto; Mariaelisa Rampudda; Roberta Ramonda; Luca Iaccarino; Andrea Doria
Journal:  Autoimmun Rev       Date:  2011-01-09       Impact factor: 9.754

3.  Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.

Authors:  Joseph Pidala; Marcie Tomblyn; Taiga Nishihori; Teresa Field; Ernesto Ayala; Janelle Perkins; Hugo Fernandez; Fred Locke; Lia Perez; Jose Leonel Ochoa; Melissa Alsina; Claudio Anasetti
Journal:  Haematologica       Date:  2011-05-12       Impact factor: 9.941

4.  Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

Authors:  Daniel Wolff; Michael Schleuning; Stephanie von Harsdorf; Ulrike Bacher; Armin Gerbitz; Michael Stadler; Francis Ayuk; Alexander Kiani; Rainer Schwerdtfeger; Georgia B Vogelsang; Guido Kobbe; Martin Gramatzki; Anita Lawitschka; Mohamad Mohty; Steven Z Pavletic; Hildegard Greinix; Ernst Holler
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-26       Impact factor: 5.742

Review 5.  How I treat chronic graft-versus-host disease.

Authors:  G B Vogelsang
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

6.  A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment.

Authors:  P J Martin; G Schoch; L Fisher; V Byers; C Anasetti; F R Appelbaum; P G Beatty; K Doney; G B McDonald; J E Sanders
Journal:  Blood       Date:  1990-10-15       Impact factor: 22.113

7.  A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease.

Authors:  L Cragg; B R Blazar; T Defor; N Kolatker; W Miller; J Kersey; M Ramsay; P McGlave; A Filipovich; D Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

8.  Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease.

Authors:  A I Benito; T Furlong; P J Martin; C Anasetti; F R Appelbaum; K Doney; R A Nash; T Papayannopoulou; R Storb; K M Sullivan; R Witherspoon; H J Deeg
Journal:  Transplantation       Date:  2001-12-27       Impact factor: 4.939

9.  Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone.

Authors:  H J Deeg; T P Loughran; R Storb; M S Kennedy; K M Sullivan; K Doney; F R Appelbaum; E D Thomas
Journal:  Transplantation       Date:  1985-08       Impact factor: 4.939

10.  Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids.

Authors:  K C Doney; P L Weiden; R Storb; E D Thomas
Journal:  Am J Hematol       Date:  1981       Impact factor: 10.047
View more
  5 in total

1.  Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10.

Authors:  Y Peng; X Chen; Q Liu; X Zhang; K Huang; L Liu; H Li; M Zhou; F Huang; Z Fan; J Sun; Q Liu; M Ke; X Li; Q Zhang; A P Xiang
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

2.  Gamma irradiation preserves immunosuppressive potential and inhibits clonogenic capacity of human bone marrow-derived mesenchymal stromal cells.

Authors:  Ana Valéria Gouveia de Andrade; Julia Riewaldt; Rebekka Wehner; Marc Schmitz; Marcus Odendahl; Martin Bornhäuser; Torsten Tonn
Journal:  J Cell Mol Med       Date:  2014-03-21       Impact factor: 5.310

3.  Soluble DNAM-1, as a Predictive Biomarker for Acute Graft-Versus-Host Disease.

Authors:  Minoru Kanaya; Kazuko Shibuya; Rei Hirochika; Miyoko Kanemoto; Kazuteru Ohashi; Masafumi Okada; Yukiko Wagatsuma; Yukiko Cho; Hiroshi Kojima; Takanori Teshima; Masahiro Imamura; Hisashi Sakamaki; Akira Shibuya
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

Review 4.  Resolution of Inflammation in Acute Graft-Versus-Host-Disease: Advances and Perspectives.

Authors:  Layara Roberta Ferreira Duarte; Vanessa Pinho; Barbara Maximino Rezende; Mauro Martins Teixeira
Journal:  Biomolecules       Date:  2022-01-05

5.  Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells.

Authors:  Hannes Schmid; Emmanuelle M Ribeiro; Kathy-Ann Secker; Silke Duerr-Stoerzer; Hildegard Keppeler; Ruoyun Dong; Timo Munz; Klaus Schulze-Osthoff; Stephan Hailfinger; Corina Schneidawind; Dominik Schneidawind
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.